Metformin/retagliptin - Shandong Suncadia Medicine
Alternative Names: HRX-0701; Metformin hydrochloride/Retagliptin phosphate - Shandong Suncadia MedicineLatest Information Update: 04 Dec 2023
At a glance
- Originator Shandong Suncadia Medicine
- Class Antihyperglycaemics; Biguanides; Carboxylic acids; Fluorobenzenes; Imidazoles; Pyrazines; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
Most Recent Events
- 04 Dec 2023 Preregistration for Type 2 diabetes mellitus (PO), prior to December 2023 (Jiangsu Hengrui Medicine pipeline, December 2023)
- 08 Aug 2022 Shandong Suncadia Medicine completes a phase I trial in Type 2 diabetes mellitus (In volunteers) in China (PO) (NCT05415644))
- 05 Jul 2022 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in China (PO) (NCT05415644)